Parkinson’s disease(PD)is the second most common degenerative neurological disorder after Alzheimer’s disease.As one of fastest growing neurological conditions,PD affects millions of elderly people worldwide.PD pati...Parkinson’s disease(PD)is the second most common degenerative neurological disorder after Alzheimer’s disease.As one of fastest growing neurological conditions,PD affects millions of elderly people worldwide.PD patients display progressive motor symptoms,including resting tremor,slowed movement,impaired posture and balance,and rigid muscles[1].Additionally,they also often suffer from chronic pain,depression,dementia,and other non-motor symptoms[2].Medications and surgery can improve patient’s motor performance to some degree,while the treatment for non-motor conditions is limited.Moreover,long-term medication can cause severe side effects,such as dyskinesia and impulse control disorders[3,4].Therefore,new mechanistic insights and therapeutic agents/procedures are still needed to improve the treatment of increasing number of PD patients.展开更多
基金supported by the Intramural Research Programs of National Institute on Aging,NIH(HC,ZIA AG000944,AG000928).
文摘Parkinson’s disease(PD)is the second most common degenerative neurological disorder after Alzheimer’s disease.As one of fastest growing neurological conditions,PD affects millions of elderly people worldwide.PD patients display progressive motor symptoms,including resting tremor,slowed movement,impaired posture and balance,and rigid muscles[1].Additionally,they also often suffer from chronic pain,depression,dementia,and other non-motor symptoms[2].Medications and surgery can improve patient’s motor performance to some degree,while the treatment for non-motor conditions is limited.Moreover,long-term medication can cause severe side effects,such as dyskinesia and impulse control disorders[3,4].Therefore,new mechanistic insights and therapeutic agents/procedures are still needed to improve the treatment of increasing number of PD patients.
